These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1627 related articles for article (PubMed ID: 25231526)

  • 1. The role of iron in brain ageing and neurodegenerative disorders.
    Ward RJ; Zucca FA; Duyn JH; Crichton RR; Zecca L
    Lancet Neurol; 2014 Oct; 13(10):1045-60. PubMed ID: 25231526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ageing, neuroinflammation and neurodegeneration.
    Ward RJ; Dexter DT; Crichton RR
    Front Biosci (Schol Ed); 2015 Jun; 7(1):189-204. PubMed ID: 25961695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron chelation and neuroprotection in neurodegenerative diseases.
    Li X; Jankovic J; Le W
    J Neural Transm (Vienna); 2011 Mar; 118(3):473-7. PubMed ID: 21161300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review on iron chelators as potential therapeutic agents for the treatment of Alzheimer's and Parkinson's diseases.
    Singh YP; Pandey A; Vishwakarma S; Modi G
    Mol Divers; 2019 May; 23(2):509-526. PubMed ID: 30293116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
    Youdim MB; Fridkin M; Zheng H
    J Neural Transm (Vienna); 2004 Oct; 111(10-11):1455-71. PubMed ID: 15480846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases.
    Zheng H; Weiner LM; Bar-Am O; Epsztejn S; Cabantchik ZI; Warshawsky A; Youdim MB; Fridkin M
    Bioorg Med Chem; 2005 Feb; 13(3):773-83. PubMed ID: 15653345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition.
    Zheng H; Gal S; Weiner LM; Bar-Am O; Warshawsky A; Fridkin M; Youdim MB
    J Neurochem; 2005 Oct; 95(1):68-78. PubMed ID: 16181413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.
    Youdim MB; Stephenson G; Ben Shachar D
    Ann N Y Acad Sci; 2004 Mar; 1012():306-25. PubMed ID: 15105275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multifunctional activities of green tea catechins in neuroprotection. Modulation of cell survival genes, iron-dependent oxidative stress and PKC signaling pathway.
    Mandel SA; Avramovich-Tirosh Y; Reznichenko L; Zheng H; Weinreb O; Amit T; Youdim MB
    Neurosignals; 2005; 14(1-2):46-60. PubMed ID: 15956814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroprotective multifunctional iron chelators: from redox-sensitive process to novel therapeutic opportunities.
    Weinreb O; Amit T; Mandel S; Kupershmidt L; Youdim MB
    Antioxid Redox Signal; 2010 Sep; 13(6):919-49. PubMed ID: 20095867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding the Role of Hypoxia Inducible Factor During Neurodegeneration for New Therapeutics Opportunities.
    Merelli A; Rodríguez JCG; Folch J; Regueiro MR; Camins A; Lazarowski A
    Curr Neuropharmacol; 2018; 16(10):1484-1498. PubMed ID: 29318974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brain iron accumulation in aging and neurodegenerative disorders.
    Hagemeier J; Geurts JJ; Zivadinov R
    Expert Rev Neurother; 2012 Dec; 12(12):1467-80. PubMed ID: 23237353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel therapeutic approach for neurodegenerative pathologies: multitarget iron-chelating drugs regulating hypoxia-inducible factor 1 signal transduction pathway.
    Weinreb O; Amit T; Mandel S; Youdim MB
    Neurodegener Dis; 2012; 10(1-4):112-5. PubMed ID: 22156453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iron, brain ageing and neurodegenerative disorders.
    Zecca L; Youdim MB; Riederer P; Connor JR; Crichton RR
    Nat Rev Neurosci; 2004 Nov; 5(11):863-73. PubMed ID: 15496864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic applications of chelating drugs in iron metabolic disorders of the brain and retina.
    Shahandeh A; Bui BV; Finkelstein DI; Nguyen CTO
    J Neurosci Res; 2020 Oct; 98(10):1889-1904. PubMed ID: 32643793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron Metabolism in Aging and Age-Related Diseases.
    Tian Y; Tian Y; Yuan Z; Zeng Y; Wang S; Fan X; Yang D; Yang M
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurodegenerative diseases and therapeutic strategies using iron chelators.
    Ward RJ; Dexter DT; Crichton RR
    J Trace Elem Med Biol; 2015; 31():267-73. PubMed ID: 25716300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Green tea catechins as brain-permeable, non toxic iron chelators to "iron out iron" from the brain.
    Mandel S; Weinreb O; Reznichenko L; Kalfon L; Amit T
    J Neural Transm Suppl; 2006; (71):249-57. PubMed ID: 17447435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iron: a new target for pharmacological intervention in neurodegenerative diseases.
    Whitnall M; Richardson DR
    Semin Pediatr Neurol; 2006 Sep; 13(3):186-97. PubMed ID: 17101458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate.
    Mandel S; Maor G; Youdim MB
    J Mol Neurosci; 2004; 24(3):401-16. PubMed ID: 15655262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 82.